Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DCLK1 | O15075 | 11/20 | 0.53 |
| ▸ | LRRK2 | Q5S007 | 11/20 | 0.53 |
| ▸ | MAPK7 | Q13164 | 9/20 | 0.52 |
| ▸ | BRD4 | O60885 | 4/20 | 0.47 |
| ▸ | PIK3CD | O00329 | 3/20 | 0.39 |
| ▸ | AURKA | O14965 | 3/20 | 0.39 |
| ▸ | PIK3C2G | O75747 | 3/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.39 |
| ▸ | DRD2 | P14416 | 2/20 | 0.38 |
| ▸ | HTR6 | P50406 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | DRD1 | P21728 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20094162 | 0.86 | MAPK7 (0.51) | DCLK1LRRK2MAPK7BRD4PIK3CD | |
| SCHEMBL10098691 | 0.81 | MAPK7 (0.56) | DCLK1LRRK2MAPK7BRD4PIK3CD | |
| SCHEMBL20094145 | 0.76 | LRRK2 (0.50) | DCLK1LRRK2MAPK7BRD4PIK3CD | |
| SCHEMBL19496544 | 0.72 | MAPK7 (0.52) | DCLK1LRRK2MAPK7BRD4PIK3CD | |
| SCHEMBL20094174 | 0.70 | LRRK2 (1.00) | DCLK1LRRK2MAPK7BRD4 | |
| SCHEMBL15218930 | 0.70 | PSEN1 (0.46) | — | |
| SCHEMBL9372896 | 0.69 | ALDH1A1 (0.47) | DCLK1LRRK2MAPK7BRD4DRD2 | |
| SCHEMBL10098791 | 0.69 | TNK2 (0.56) | LRRK2MAPK7 | |
| SCHEMBL25357908 | 0.68 | DCLK1 (0.52) | DCLK1LRRK2MAPK7BRD4PIK3CD | |
| SCHEMBL30526068 | 0.68 | DCLK1 (0.52) | DCLK1LRRK2MAPK7BRD4PIK3CD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3528814-B1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DCLK1/2-MEDIATED DISORDERS | DANA FARBER CANCER INST INC (US) | 2024-08-14 | — | — | EP | disclosed |
| US-11028089-B2 | Pyrimido-diazepinone kinase scaffold compounds and methods of treating DCLK1/2-mediated disorders | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-06-08 | — | — | US | disclosed |
| US-20190315753-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DCLK1/2-MEDIATED DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2019-10-17 | — | — | US | disclosed |
| WO-2018075608-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DCLK1/2-MEDIATED DISORDERS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2018-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190315753-A1 | PYRIMIDO-DIAZEPINONE KINASE SCAFFOLD COMPOUNDS AND METHODS OF TREATING DCLK1/2-MEDIATED DISORDERS | CAMK1, CAMKK2, DCLK2 | DCLK1 7/4885LRRK2 162/4885MAPK7 589/4885 |
| US-11028089-B2 | Pyrimido-diazepinone kinase scaffold compounds and methods of treating DCLK1/2-mediated disorders | CAMK1, CAMKK2, DCLK2 | DCLK1 7/4885LRRK2 162/4885MAPK7 589/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.